

Irene Lorand-Metze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5513988/publications.pdf>

Version: 2024-02-01

178
papers

2,556
citations

218592

26
h-index

302012

39
g-index

182
all docs

182
docs citations

182
times ranked

3310
citing authors

#	ARTICLE	IF	CITATIONS
1	The Fractal Dimension Suggests Two Chromatin Configurations in Small Cell Neuroendocrine Lung Cancer and Is an Independent Unfavorable Prognostic Factor for Overall Survival. <i>Microscopy and Microanalysis</i> , 2022, , 1-5.	0.2	2
2	Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia. <i>EJHaem</i> , 2022, 3, 698-706.	0.4	1
3	Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease. <i>British Journal of Haematology</i> , 2021, 192, 129-136.	1.2	5
4	Fluorescence lifetime imaging is able to recognize different hematopoietic precursors in unstained routine bone marrow films. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 641-646.	1.1	1
5	Updating recommendations of the Brazilian Group of Flow Cytometry (GBCFLUX) for diagnosis of acute leukemias using four-color flow cytometry panels. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 499-506.	0.1	2
6	Using Antigen Expression of Leukemic Cells for a Fast Screening of Acute Promyelocytic Leukemia by Flow Cytometry. <i>Diagnostics</i> , 2021, 11, 1988.	1.3	0
7	The Importance of Bone Marrow Lymphocyte Subtypes As Predicting Factors for Molecular Recurrence in Patients with Chronic Myeloid Leukemia after Discontinuation of Imatinib. <i>Blood</i> , 2021, 138, 2564-2564.	0.6	0
8	Metabolic Volume Measurements in Multiple Myeloma. <i>Metabolites</i> , 2021, 11, 875.	1.3	4
9	A simple score derived from bone marrow immunophenotyping is important for prognostic evaluation in myelodysplastic syndromes. <i>Scientific Reports</i> , 2020, 10, 20281.	1.6	3
10	Scoring of PD-L1 positivity: Are we analyzing enough cells?. <i>Cancer Cytopathology</i> , 2020, 128, 424-424.	1.4	0
11	Chédiak-Higashi syndrome approached by several different microscopy imaging technologies. <i>British Journal of Haematology</i> , 2020, 189, 1001-1001.	1.2	1
12	Computed tomography-based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma. <i>Nuclear Medicine Communications</i> , 2020, 41, 377-382.	0.5	13
13	^{99m} Tc-sestamibi SPECT/CT and ¹⁸ F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma. <i>Nuclear Medicine Communications</i> , 2020, 41, 1081-1088.	0.5	9
14	Developing a Simple Algorithm Based on Multiparameter Flow Cytometry for Fast Screening of Acute Promyelocytic Leukemia. <i>Blood</i> , 2020, 136, 25-26.	0.6	0
15	Proposal for a Quantitative ¹⁸ F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma. <i>Scientific Reports</i> , 2019, 9, 16429.	1.6	26
16	Flow cytometry "Ogata score" for the diagnosis of myelodysplastic syndromes in a real-life setting. A Latin American experience. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 536-541.	0.7	8
17	Managing costs in primary immunodeficiency: minimal immunophenotyping and three national references. <i>Apmis</i> , 2019, 127, 228-235.	0.9	2
18	Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world. <i>Leukemia Research</i> , 2019, 79, 69-74.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 162-166.	0.2	13
20	IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 92-95.	0.1	0
21	Normal variation of bone marrow B-cell precursors according to age – reference ranges for studies in myelodysplastic syndromes in Brazil. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 800-806.	0.7	9
22	Guidelines on myelodysplastic syndromes: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 255-261.	0.1	1
23	Part 2: Myelodysplastic syndromes – classification systems. <i>Hematology, Transfusion and Cell Therapy</i> , 2018, 40, 262-266.	0.1	3
24	Lowering the p-value from 0.05 to 0.005 conflicts with the 3R rules – an advocacy for alternatives to hypothesis testing with the p-value approach. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2018, 35, 516-517.	0.9	2
25	The World Health Organisation classification of myelodysplastic syndromes contains prognostically relevant information beyond the prognostic scores IPSS-R or WPSS. <i>European Journal of Cancer</i> , 2017, 72, 266-268.	1.3	3
26	Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 728-733.	0.2	26
27	SIVA, a target of p53, is downregulated in myelodysplastic syndromes. <i>Applied Cancer Research</i> , 2017, 37, .	1.0	0
28	Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26285.	0.8	14
29	Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up. <i>Oncology Letters</i> , 2016, 12, 485-487.	0.8	10
30	Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 346-357.	0.7	24
31	Monocyte phenotypic aberrancies are an unfavorable prognostic factor in patients with myelodysplastic syndromes and low IPSS-R scores. <i>Cellular Immunology</i> , 2016, 310, 212-213.	1.4	4
32	Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. <i>Diagnostic Pathology</i> , 2016, 11, 28.	0.9	16
33	Imbalance between proliferation and in vitro apoptosis rates predicts progression in chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2016, 90, 484-485.	0.7	1
34	IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. <i>Oncotarget</i> , 2016, 7, 6948-6959.	0.8	20
35	Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting. <i>Blood</i> , 2015, 126, 1863-1865.	0.6	10
36	Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil. <i>Clinics</i> , 2015, 70, 322-325.	0.6	7

#	ARTICLE	IF	CITATIONS
37	Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors. <i>Diagnostic Pathology</i> , 2015, 10, 44.	0.9	14
38	Tenâ€Elevenâ€Translocation 2 (<sc>TET</sc>2) is downregulated in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2015, 94, 413-418.	1.1	18
39	BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution. <i>Acta Haematologica</i> , 2015, 134, 248-254.	0.7	9
40	Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 211-214.	0.7	2
41	Umbilical cord blood <sc>CD</sc>34⁺ stem cells and other mononuclear cell subtypes processed up to 96Âh from collection and stored at room temperature maintain a satisfactory functionality for cell therapy. <i>Vox Sanguinis</i> , 2015, 108, 72-81.	0.7	8
42	Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Blood</i> , 2015, 126, 4031-4031.	0.6	1
43	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. <i>Oncotarget</i> , 2015, 6, 29573-29584.	0.8	16
44	Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors â€ a single center experience. <i>Clinics</i> , 2015, 70, 550-555.	0.6	19
45	Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 442-444.	0.7	1
46	Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. <i>Leukemia Research</i> , 2014, 38, 251-257.	0.4	28
47	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. <i>Leukemia Research</i> , 2014, 38, 1245-1251.	0.4	47
48	Viability of umbilical cord blood mononuclear cell subsets until 96 hours after collection. <i>Transfusion</i> , 2013, 53, 2034-2042.	0.8	11
49	Quantifying loss of CD34+ cells collected by apheresis after processing for freezing and post-thaw. <i>Transfusion and Apheresis Science</i> , 2013, 48, 241-246.	0.5	25
50	A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. <i>Critical Care</i> , 2013, 17, R169.	2.5	24
51	Participation of leptin in the determination of the macrophage phenotype: an additional role in adipocyte and macrophage crosstalk. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2013, 49, 473-478.	0.7	60
52	Adherence to Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: A Brazilian Single-Center Cohort. <i>Acta Haematologica</i> , 2013, 130, 16-22.	0.7	34
53	Immunophenotyping in Myelodysplastic Syndromes Can Add Prognostic Information to Well-Established and New Clinical Scores. <i>PLoS ONE</i> , 2013, 8, e81048.	1.1	22
54	Circulating Progenitor and Mature Endothelial Cells in Deep Vein Thrombosis. <i>International Journal of Medical Sciences</i> , 2013, 10, 1746-1754.	1.1	26

#	ARTICLE	IF	CITATIONS
55	Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. Clinics, 2013, 68, 339-343.	0.6	9
56	Diagnosis of Scott syndrome in patient with bleeding disorder of unknown cause. Blood Coagulation and Fibrinolysis, 2012, 23, 75-77.	0.5	10
57	Molecular characteristics and chromatin texture features in acute promyelocytic leukemia. Diagnostic Pathology, 2012, 7, 75.	0.9	10
58	Lipopolysaccharide treatment reduces rat platelet aggregation independent of intracellular reactive-oxygen species generation. Platelets, 2012, 23, 195-201.	1.1	17
59	Polymorphisms of <i>VEGF</i> , <i>GSTM1</i> and <i>GSTT1</i> genes in multiple myeloma risk. Hematological Oncology, 2012, 30, 105-107.	0.8	5
60	Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. American Journal of Hematology, 2012, 87, 948-952.	2.0	63
61	Downregulation of IRS2 in myelodysplastic syndrome: A possible role in impaired hematopoietic cell differentiation. Leukemia Research, 2012, 36, 931-935.	0.4	14
62	Expression profiles of phosphatidylinositol phosphate kinase genes during normal human in vitro erythropoiesis. Genetics and Molecular Research, 2012, 11, 3861-3868.	0.3	3
63	Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses. Blood, 2012, 120, 3787-3787.	0.6	1
64	A High Angiopoietin-2/Angiopoietin-1 Ratio Independently Predicts Septic Shock Development in Patients with Chemotherapy-Associated Febrile Neutropenia and Hematological Malignancies.. Blood, 2012, 120, 2154-2154.	0.6	0
65	ANKHD1 Interacts with the Proapoptotic Protein SIVA and Plays a Role in the Proliferation and Stathmin Activation of Acute Leukemia Cells.. Blood, 2012, 120, 2419-2419.	0.6	0
66	Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study. Journal of Translational Medicine, 2011, 9, 23.	1.8	29
67	Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase. Revista Brasileira De Hematologia E Hemoterapia, 2011, 33, 211-215.	0.7	14
68	Fractal Characteristics of May-Grünwald-Giemsa Stained Chromatin Are Independent Prognostic Factors for Survival in Multiple Myeloma. PLoS ONE, 2011, 6, e20706.	1.1	50
69	<i>Ex vivo</i> Expansion of CD56 ⁺ NK and NKT-like Lymphocytes from Peripheral Blood Mononuclear Cells of Patients with Ovarian Neoplasia. Scandinavian Journal of Immunology, 2011, 74, 244-252.	1.3	11
70	The impact of maternal HIV infection on cord blood lymphocyte subsets and cytokine profile in exposed non-infected newborns. BMC Infectious Diseases, 2011, 11, 38.	1.3	51
71	Alterations in cell maturity and serum survival factors may modulate neutrophil numbers in sickle cell disease. Experimental Biology and Medicine, 2011, 236, 1239-1246.	1.1	8
72	Evaluation of Thrombin Generation in the Early Stages of Sepsis in Patients with Hematological Malignancies and Febrile Neutropenia,. Blood, 2011, 118, 3347-3347.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia. <i>BMC Infectious Diseases</i> , 2010, 10, 143.	1.3	26
74	Treatment Outcome of Acute Promyelocytic Leukemia with Modified Aida Protocol. <i>Advances in Hematology</i> , 2010, 2010, 1-3.	0.6	2
75	Mechanisms underlying the inhibitory effects of lipopolysaccharide on human platelet adhesion. <i>Platelets</i> , 2010, 21, 260-269.	1.1	13
76	Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2215-2221.	0.6	15
77	Molecular identification of the HLA-DRB1-DQB1 for diagnosis and follow-up of acute leukemias. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 44, 69-73.	0.6	14
78	The impact of several phenotypic features at diagnosis on survival of patients with myelodysplastic syndromes. <i>Neoplasma</i> , 2010, 57, 530-536.	0.7	7
79	Chromatin Texture and Molecular Features Are Independent Prognostic Factors In AML. <i>Blood</i> , 2010, 116, 4850-4850.	0.6	1
80	No contribution of GSTM1 and GSTT1 null genotypes to the risk of neutropenia due to benzene exposure in Southeastern Brazil. <i>Genetics and Molecular Biology</i> , 2009, 32, 709-711.	0.6	2
81	Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. <i>Platelets</i> , 2009, 20, 367-375.	1.1	23
82	Y12 Diagnostic utility of a small four color panel for flow cytometric analysis in myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, S55.	0.4	0
83	P024 Computerized nuclear texture analysis for the characterization of atypic immature cells in MDS. <i>Leukemia Research</i> , 2009, 33, S71-S72.	0.4	0
84	P079 Increase in bone marrow immature nonlymphoid early precursors are indicative of a short survival in myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, S104.	0.4	0
85	Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage. <i>Leukemia</i> , 2009, 23, 144-152.	3.3	15
86	Polymorphisms of glutathione S-transferase Mu 1, glutathione S-transferase theta 1 and glutathione S-transferase Pi 1 genes in Hodgkin's lymphoma susceptibility and progression. <i>Leukemia and Lymphoma</i> , 2009, 50, 1005-1009.	0.6	9
87	Brazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 449-454.	1.4	4
88	Goodness-of-fit of the fractal dimension as a prognostic factor. <i>Cellular Oncology</i> , 2009, 31, 503-4.	1.9	8
89	VARIATION OF BONE MARROW CD34+ CELL SUBSETS IN MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO TYPES. <i>Neoplasma</i> , 2009, 56, 435-440.	0.7	8
90	Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. <i>Leukemia Research</i> , 2008, 32, 401-405.	0.4	32

#	ARTICLE	IF	CITATIONS
91	The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. <i>Leukemia Research</i> , 2008, 32, 211-213.	0.4	20
92	An algorithm based on peripheral CD34+ cells and hemoglobin concentration provides a better optimization of apheresis than the application of a fixed CD34 threshold. <i>Transfusion</i> , 2008, 48, 1133-1137.	0.8	10
93	The influence of storage and leukocyte depletion on the antigen densities of FY1, FY2, MNS3 and MNS4 measured by flow cytometry. <i>Transfusion and Apheresis Science</i> , 2008, 38, 101-107.	0.5	5
94	The rare t(6;8) (q27;p11) translocation in a case of chronic myeloid neoplasm mimicking polycythemia vera. <i>Leukemia and Lymphoma</i> , 2008, 49, 1832-1835.	0.6	7
95	Low expression of APAF-1XL in acute myeloid leukemia may be associated with the failure of remission induction therapy. <i>Brazilian Journal of Medical and Biological Research</i> , 2008, 41, 571-578.	0.7	6
96	Thalidomide + Dexamethasone as Maintenance after Single Autologous Stem Cell Transplantation Improves Progression-Free Survival (PFS) in Advanced Multiple Myeloma. A Prospective Brazilian Randomized Trial. <i>Blood</i> , 2008, 112, 3703-3703.	0.6	5
97	The importance of the detection of MRD at the end of induction chemotherapy in childhood ALL. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2008, 30, .	0.7	0
98	Phenotypic subtypes of acute lymphoblastic leukemia associated with different nuclear chromatin texture. , 2008, 30, 92-8.		8
99	Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. <i>Leukemia Research</i> , 2007, 31, 147-155.	0.4	53
100	Expressions of the VLA-4, LFA-1 and Mac-1 integrins in eosinophil migration in a case of chronic eosinophilic leukaemia. <i>Leukemia Research</i> , 2007, 31, 695-697.	0.4	1
101	Reduced expression of FLIPSHORT in bone marrow of low risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2007, 31, 853-857.	0.4	4
102	Early proliferation of umbilical cord blood cells from premature neonates. <i>Vox Sanguinis</i> , 2007, 93, 145-153.	0.7	7
103	GSTM1 and codon 72 P53 polymorphism in multiple myeloma. <i>Annals of Hematology</i> , 2007, 86, 815-819.	0.8	14
104	JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia. <i>Genetics and Molecular Biology</i> , 2007, 30, 336-338.	0.6	9
105	High Dose Sequential (HDS) Followed by Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Salvage Treatment of Hodgkin's Disease (HD): A Brazilian Experience.. <i>Blood</i> , 2007, 110, 5103-5103.	0.6	0
106	Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF. <i>Transfusion and Apheresis Science</i> , 2006, 34, 33-40.	0.5	10
107	Contribuiç~o da citometria de fluxo para o diagn~stico e progn~stico das s~ndromes mielodispl~sicas. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2006, 28, 178.	0.7	1
108	Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. <i>Leukemia Research</i> , 2006, 30, 9-16.	0.4	29

#	ARTICLE	IF	CITATIONS
109	Causes of incidental neutropenia in adulthood. <i>Annals of Hematology</i> , 2006, 85, 705-709.	0.8	35
110	Leptin Inhibits Apoptosis in Thymus through a Janus Kinase-2-Independent, Insulin Receptor Substrate-1/Phosphatidylinositol-3 Kinase-Dependent Pathway. <i>Endocrinology</i> , 2006, 147, 5470-5479.	1.4	47
111	Frontline Therapy with Early Intensification and Autologous Stem Cell Transplantation versus Conventional Chemotherapy in Unselected High-Risk, Aggressive Non-Hodgkin's Lymphoma Patients: A Prospective Randomized GEMOH Report. <i>Acta Haematologica</i> , 2006, 115, 15-21.	0.7	14
112	Pancytopenia in Untreated Patients with Graves' Disease. <i>Thyroid</i> , 2006, 16, 403-409.	2.4	54
113	Síndrome mielodisplásica na infância. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2006, 28, .	0.7	2
114	The Fractal Dimension of Nuclear Chromatin as a Prognostic Factor in Acute Precursor B Lymphoblastic Leukemia. <i>Analytical Cellular Pathology</i> , 2006, 28, 55-59.	0.7	24
115	Interaction of clinical, genetic and molecular features in chronic lymphocytic leukemia. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2006, 28, .	0.7	1
116	Síndromes mielodisplásicas, sua importância no nosso meio. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2006, 28, .	0.7	0
117	Characterization of Gene Expression Profiles of Plasma Cells in Patients with Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5082-5082.	0.6	0
118	Phenotypic quantitative features of patients with acute myeloid leukemia. <i>Neoplasma</i> , 2006, 53, 155-60.	0.7	8
119	LLC: critérios diagnósticos, imunofenotipagem e diagnóstico diferencial. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2005, 27, 233.	0.7	2
120	Bone Marrow Features in Children with HIV Infection and Peripheral Blood Cytopenias. <i>Journal of Tropical Pediatrics</i> , 2005, 51, 114-119.	0.7	26
121	Effect of Cytokines and Chemokines on Sickle Neutrophil Adhesion to Fibronectin. <i>Acta Haematologica</i> , 2005, 113, 130-136.	0.7	41
122	Spontaneous Apoptosis in Chronic Lymphocytic Leukemia Is Not an Independent Prognostic Factor for Stability of Disease When Compared with Combined AgNOR and TTM Scores. <i>Analytical Cellular Pathology</i> , 2005, 27, 199-201.	0.7	5
123	Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 538-542.	1.3	30
124	Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. <i>Leukemia Research</i> , 2004, 28, 587-594.	0.4	54
125	Flow Cytometric Analysis of the Expression of Fas/FasI in Bone Marrow CD34+ Cells in Myelodysplastic Syndromes: Relation to Disease Progression. <i>Leukemia and Lymphoma</i> , 2004, 45, 309-313.	0.6	17
126	Inherited Mutation in Exon 2 of GATA-1 Is Associated with a Clinical and Laboratory Picture Similar to Familial Hypocellular Myelodysplastic Syndrome (MDS).. <i>Blood</i> , 2004, 104, 3432-3432.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Proliferation in Non-Hodgkin's Lymphomas and Its Prognostic Value Related to Staging Parameters. <i>Analytical Cellular Pathology</i> , 2004, 26, 63-71.	0.7	8
128	A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma. <i>Annals of Hematology</i> , 2003, 82, 405-409.	0.8	5
129	The Prognostic Relevance of Apoptosis-related Proteins in Classical Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 2003, 44, 483-488.	0.6	23
130	Acute leukemias in Piauí: comparison with features observed in other regions of Brazil. <i>Brazilian Journal of Medical and Biological Research</i> , 2003, 36, 331-337.	0.7	28
131	Nódulos linfóides medulares. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2003, 25, 81.	0.7	1
132	Mutations in the p53 Gene in Acute Myeloid Leukemia Patients Correlate with Poor Prognosis. <i>Hematology</i> , 2002, 7, 13-19.	0.7	22
133	Bone marrow lymphoid aggregates in myelodysplastic syndromes: incidence, immunomorphological characteristics and correlation with clinical features and survival. <i>Leukemia Research</i> , 2002, 26, 525-530.	0.4	16
134	The Brazilian pediatric myelodysplastic cooperative group strategies: are they relevant to improve educational approach and correct diagnosis?. <i>Leukemia Research</i> , 2002, 26, 637-642.	0.4	10
135	Magnetic Resonance Imaging of Femoral Marrow Cellularity in Hypocellular Haemopoietic Disorders. <i>Clinical Radiology</i> , 2001, 56, 107-110.	0.5	5
136	Multiple lymphoid nodules in bone marrow biopsy in immunocompetent patient with cytomegalovirus infection: an immunohistochemical analysis. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2001, 34, 365-368.	0.4	8
137	Analysis of $t(8;21)(q22;q22)$ trans -rearrangements in paediatric patients undergoing chemotherapy. <i>British Journal of Haematology</i> , 2001, 113, 1001-1008.	1.2	7
138	Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters. <i>Cytometry</i> , 2001, 46, 329-335.	1.8	30
139	p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. <i>American Journal of Hematology</i> , 2001, 67, 84-92.	2.0	43
140	Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface. <i>British Journal of Pharmacology</i> , 2001, 134, 632-638.	2.7	39
141	Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. <i>European Journal of Haematology</i> , 2001, 66, 383-388.	1.1	69
142	Expression of Epstein-Barr virus in classical Hodgkin's lymphomas in Brazilian adult patients. <i>Haematologica</i> , 2001, 86, 1227-8.	1.7	22
143	Nucleolus organizer regions (AgNORs) and total tumor mass are independent prognostic parameters for treatment-free period in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2000, 89, 440-443.	2.3	30
144	Sideroblastic anemia following treatment of chronic myeloid leukemia with busulfan. <i>Leukemia</i> , 2000, 14, 214-215.	3.3	8

#	ARTICLE	IF	CITATIONS
145	Early total white blood cell recovery is a predictor of low number of apheresis and good CD34+ cell yield. <i>Transfusion Science</i> , 2000, 23, 91-100.	0.6	15
146	Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience. <i>Sao Paulo Medical Journal</i> , 2000, 118, 173-178.	0.4	15
147	Vanishing bile duct syndrome in Hodgkin's disease: case report. <i>Sao Paulo Medical Journal</i> , 2000, 118, 154-157.	0.4	22
148	Methods for analysing AgNORs. <i>Journal of Clinical Pathology</i> , 1999, 52, 550a-550a.	1.0	6
149	Changes in AgNOR configurations during the evolution and treatment of chronic lymphocytic leukemia. <i>Hematology and Cell Therapy</i> , 1999, 41, 205-210.	0.7	11
150	CHILDHOOD MYELODYSPLASTIC SYNDROMES IN A BRAZILIAN POPULATION. <i>Pediatric Hematology and Oncology</i> , 1999, 16, 347-353.	0.3	14
151	Age related decrease of AgNOR activity in acute and chronic lymphocytic leukaemias. <i>Journal of Clinical Pathology</i> , 1999, 52, 52-52.	2.1	4
152	The differential diagnosis between aplastic anemia and hypocellular myelodysplasia in patients with pancytopenia. <i>Haematologica</i> , 1999, 84, 564-5.	1.7	17
153	A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. <i>Bone Marrow Transplantation</i> , 1998, 22, 1145-1151.	1.3	178
154	Molecular analysis of the retinoblastoma (RB1) gene in acute myeloid leukemia patients. <i>Leukemia Research</i> , 1998, 22, 787-792.	0.4	11
155	Relationship between morphometric analysis of nucleolar organizer regions and cell proliferation in acute leukemias. , 1998, 32, 51-56.		22
156	Treatment of prolymphocytic leukemia with cladribine. <i>Annals of Hematology</i> , 1998, 76, 85-86.	0.8	9
157	âœN-rasGene Point Mutations in Brazilian Acute Myelogenous Leukemia Patients Correlate with a Poor Prognosissâœ. <i>Leukemia and Lymphoma</i> , 1997, 24, 309-317.	0.6	26
158	Lymphoblastic transformation of myelodysplastic syndrome. <i>Sao Paulo Medical Journal</i> , 1997, 115, 1508-1512.	0.4	9
159	Hemophagocytic syndrome: pitfalls in its diagnosis. <i>Sao Paulo Medical Journal</i> , 1997, 115, 1548-1552.	0.4	5
160	Hodgkin's disease in Brazil: a clinicopathologic study. <i>Haematologica</i> , 1997, 82, 127-8.	1.7	10
161	AgNOR clusters as a parameter of cell kinetics in chronic lymphocytic leukaemia. <i>Journal of Clinical Pathology</i> , 1996, 49, M357-M360.	2.1	12
162	Adult T-Cell Leukemia (ATL) with an Unusual Immunophenotype and a High Cellular Proliferation Rate. <i>Leukemia and Lymphoma</i> , 1996, 22, 523-526.	0.6	18

#	ARTICLE	IF	CITATIONS
163	Changes of nucleolar organizer regions in granulopoietic precursors during the course of chronic myeloid leukemia. <i>Annals of Hematology</i> , 1995, 71, 275-279.	0.8	9
164	Association of a myelodysplastic syndrome with hairy cell leukaemia. <i>European Journal of Haematology</i> , 1995, 55, 341-343.	1.1	3
165	Changes of nucleolar organizer regions in granulopoietic precursors during the course of chronic myeloid leukemia. <i>Annals of Hematology</i> , 1995, 71, 275-279.	0.8	1
166	Histiocytic necrotizing lymphadenitis in Brazil: Report of a case and review of the literature. <i>Pathology International</i> , 1994, 44, 548-550.	0.6	2
167	Bone Marrow Morphology in Patients with Neutropenia Due to Chronic Exposure to Organic Solvents (Benzene): Early Lesions. <i>Pathology Research and Practice</i> , 1994, 190, 151-154.	1.0	31
168	The role of bone marrow study in diagnosis and prognosis of myelodysplastic syndrome. <i>Pathologica</i> , 1994, 86, 47-51.	1.3	9
169	Pattern of nucleolar organizer regions in human leukemic cells. <i>Analytical Cellular Pathology</i> , 1993, 5, 203-12.	2.1	13
170	Rapid Method for Isolation of DNA from Glass Slide Smears for PCR. <i>Acta Haematologica</i> , 1992, 87, 214-215.	0.7	7
171	Silver staining of nucleolar organizer regions in prostatic lesions. <i>Histopathology</i> , 1992, 21, 97-98.	1.6	1
172	Acute Megakaryoblastic Leukemia: Importance of Bone Marrow Biopsy in Diagnosis. <i>Leukemia and Lymphoma</i> , 1991, 4, 75-79.	0.6	3
173	AgNOR staining in normal bone marrow cells. <i>Journal of Clinical Pathology</i> , 1991, 44, 526.	1.0	2
174	Nucleolar organizer regions in normal hematopoiesis: relationship to cellular proliferation and maturation. , 1991, 33, 1-4.		6
175	Chronic myeloid leukemia in a homosexual HIV-seropositive man. <i>Aids</i> , 1990, 4, 923.	1.0	8
176	BONE MARROW MORPHOLOGY AT DIAGNOSIS AS A PROGNOSTIC PARAMETER IN PHILADELPHIA-POSITIVE CHRONIC MYELOGENOUS LEUKAEMIA (CML). <i>British Journal of Haematology</i> , 1989, 71, 163-163.	1.2	6
177	Histological and cytological heterogeneity of bone marrow in Philadelphiaâ€positive chronic myelogenous leukaemia at diagnosis. <i>British Journal of Haematology</i> , 1987, 67, 45-49.	1.2	1
178	Histological and cytological heterogeneity of bone marrow in Philadelphia-positive chronic myelogenous leukaemia at diagnosis. <i>British Journal of Haematology</i> , 1987, 67, 45-49.	1.2	22